VEGFA and proliferative diabetic retinopathy: Recent studies proved that the intravitreal administrations of anti-VEGF agents in the cases of proliferative diabetic retinopathy, persistent neovascularization and rubeosis iridis, significantly decrease neovascularization and improve macular edema [12].